The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy

Journal:

Blood

Published:

2025-07-19

DOI:

10.1182/blood.2024027578

Affiliations:

10

Authors:

20

Go to article

Institutions	Authors	Share
The University of Dublin, Ireland	11.000000 11.000000	0.55
Royal College of Surgeons in Ireland (RCSI), Ireland	3.000000	0.15
Baxalta Innovations GmbH, Austria	2.000000	0.10
St. James's Hospital (SJH), TCD, Ireland	1.000000	0.05
University of Dundee, United Kingdom (UK)	1.000000	0.05
IMC University of Applied Sciences Krems (IMC FH Krems), Austria	1.000000	0.05
Center for Infection and Immunity of Lille (CIIL), France	1.000000	0.05

Interested in Medical Biotechnology?